Literature DB >> 6197164

Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.

S M Camiolo, G Markus, L S Englander, M R Siuta, G H Hobika, S Kohga.   

Abstract

The plasminogen activators of surgically excised prostate cancers (43 specimens) and benign prostatic hyperplasias (33 specimens) were extracted with an acetate:arginine:detergent buffer, and the activities were quantitated with azocaseinolytic tests. Immunoinhibition with anti-urokinase antibody served to distinguish between activator types. The mean activator activities (total; urokinase type; and nonurokinase type) of the neoplastic group were about 2 times higher (p less than 0.05) than that of the benign prostatic hyperplasia tissues. Each group had more non-urokinase-type activator activity relative to urokinase type. Studies with autopsy tissues (13 specimens) revealed that different anatomical compartments of the prostate contain about the same mean activator activity, indicating that the site of origin of the disease did not influence the results. Immunoperoxidase staining for urokinase revealed its presence in the tumor cells and, to a lesser extent, in the epithelial elements of some benign ducts and glands but not in the connective tissue. The secretion and synthesis of activator activities were monitored in short-term (approximately 120 hr) organ cultures (serum-free media) of 21 neoplastic tissues. On the average, about 12 times more activity (approximately 80% as urokinase type) was recovered in the media and postculture tissue extracts than was present in preculture tissues. Similar results were observed with 10 benign prostatic hyperplasia specimens. Wide individual variations were present in both groups (1.5 to 322 times more activity than the initial values). Except for one case, urokinase-type activity was secreted continuously, while nonurokinase was secreted only initially in quantities similar to that present in preculture tissue extracts. After culture, tissue explants contained higher quantities of both activator activities than were present initially. Dexamethasone (10 or 100 microM) decreased secretion and/or synthesis of activators by about 70%. This human organ culture model appears to be a reproducible system for individual tissues and may prove to be a valuable tool for further studies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6197164

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Identification of a plasminogen activator derived from nasopharyngeal carcinoma.

Authors:  T Kosugi; G W Huang; M Nakamura; S Koja; H T Nong
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

2.  Urokinase- and tissue-type plasminogen activators are suppressed by cortisol in the involuting prostate of castrated rats.

Authors:  S N Freeman; P S Rennie; J Chao; L R Lund; P A Andreasen
Journal:  Biochem J       Date:  1990-07-01       Impact factor: 3.857

3.  Tetranectin immunoreactivity in normal human tissues. An immunohistochemical study of exocrine epithelia and mesenchyme.

Authors:  L Christensen; I Clemmensen
Journal:  Histochemistry       Date:  1989

4.  In vitro inhibition of human sarcoma cells' invasive ability by bis(5-amidino-2-benzimidazolyl)methane--a novel esteroprotease inhibitor.

Authors:  D H Cresson; W C Beckman; R R Tidwell; J D Geratz; G P Siegal
Journal:  Am J Pathol       Date:  1986-04       Impact factor: 4.307

5.  Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.

Authors:  D Samid; S Shack; C E Myers
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Effect of dimethyl sulfoxide on human carcinoma cells, inhibition of plasminogen activator synthesis, change in cell morphology, and alteration of response to cholera toxin.

Authors:  L Ossowski; D Belin
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

7.  Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.

Authors:  Zhong Dong; Allen D Saliganan; Hong Meng; Sanaa M Nabha; Aaron L Sabbota; Shijie Sheng; R Daniel Bonfil; Michael L Cher
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

8.  Fibrinogen degradation product fragment D induces endothelial cell detachment by activation of cell-mediated fibrinolysis.

Authors:  M Ge; G Tang; T J Ryan; A B Malik
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

9.  Prognostic role of urokinase-type plasminogen activator in human gliomas.

Authors:  D W Hsu; J T Efird; E T Hedley-Whyte
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

10.  The relationship between inhibition of plasminogen-activator activity and prostatic involution.

Authors:  P S Rennie; J F Bowden; N Bruchovsky; H Cheng
Journal:  Biochem J       Date:  1988-06-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.